| 摘要 |
It is intended to provide a fat-soluble lipase inhibitor which can contribut e to the prevention or treatment of obesity or diseases caused by obesity due to excessive fat intake and mildly inhibit hydrolysis by lipase when added to fats and oils of any types. Namely, a lipase inhibitor containing, as the active ingredient, at least one substance which is a fat-soluble substance selected from among SLS type triacylglycerols (i.e., symmetric triacylglycerols composed of S which represents a short-chain fatty acid having from 2 to 6 carbon atoms and L which represents a long-chain fatty ac id having from 16 to 22 carbon atoms), LUU type and UUL type triacylglycerols (i.e., asymmetric triacylglycerols composed of L which represents a long-cha in fatty acid having from 16 to 22 carbon atoms and U which represents an unsaturated fatty acid having from 16 to 22 carbon atoms) and glyceryl ether lipids wherein a long-chain alkyl chain or an alkenyl chain is attached to t he 1- or 3-position of glycerol via an ether bond. |
